Article Text

A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer
  1. J.A. Roberts*,
  2. A. P. Kudelka,
  3. D. R. Spriggs,
  4. F. Muggia§,
  5. J. Lurain,
  6. W. Grove** and
  7. C. Kowal**
  1. * Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA
  1. Address for correspondence: Dr J. A. Roberts, Division of Gynecologic Oncology, D2246 Medical Professional Building, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109-0718, USA.


The platinum analog CI-973 was selected for clinical study because it is associated with fewer and milder toxicities than either cisplatin or carboplatin in experimental animals, and because it has activity against cisplatin-resistant cell lines in vitro. In this Phase 2 study, 31 women with platinum-resistant or recurrent ovarian carcinoma were treated with CI-973. Three patients achieved a complete response, defined as the disappearance of all measurable disease. The median Kaplan-Meier survival time was estimated to be approximately 7 months from the start of treatment. The most frequently occurring drug-related toxicities were neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and diarrhea. Most toxicities were mild or moderate and none resulted in withdrawal from treatment. Despite this favorable toxicity profile, the low response rate of 10% does not support further clinical development of CI-973 as treatment for ovarian cancer.

  • CI-973
  • ovarian cancer
  • Phase 2 study
  • platinum analog

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.